Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.14+0.04 (+0.17%)
Close on Nov 18, 2026Market cap $463.06MP/E –Yield –
Neurogene operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Neurogene's operating income for the twelve months ending Jun 30, 2026 was -$121.35M. For fiscal 2025 it was -$103.33M. The highest annual figure on record is -$32.62M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$103.33M | – |
| FY2024 | Dec 31, 2024 | -$82.61M | – |
| FY2023 | Dec 31, 2023 | -$55.58M | – |
| FY2022 | Dec 31, 2022 | -$56.52M | – |
| FY2021 | Dec 31, 2021 | -$60.70M | – |
| FY2020 | Dec 31, 2020 | -$33.73M | – |
| FY2019 | Dec 31, 2019 | -$70.96M | – |
| FY2018 | Dec 31, 2018 | -$32.62M | – |
| FY2017 | Dec 31, 2017 | -$51.12M | – |
| FY2016 | Dec 31, 2016 | -$37.65M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$36.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$33.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$27.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$23.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.08M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.92M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.18M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.78M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.73M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.04M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.17M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.45M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.95M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.64M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.25M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.07M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.36M | – |
| Q3 FY2019 | Sep 30, 2019 | -$59.52M | -2312.5% |
| Q2 FY2019 | Jun 30, 2019 | -$428.00K | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.30M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.20M | – |
| Q2 FY2018 | Jun 30, 2018 | $2.69M | – |
| Q4 FY2017 | Dec 31, 2017 | -$16.53M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.07M | – |
| Q2 FY2017 | Jun 30, 2017 | -$14.00M | – |
See a number that looks wrong?